Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
HAMILTON, Bermuda, April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present clinical and preclinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRß), at the 77th Annual Meeting of the Society for Investigative Dermatology (SID) at the Chicago Hilton in Chicago, IL. “The results being presented at SID provide further scientific rationale for targeting OSMRß and dual pathway inhibition of IL-31 and OSM via KPL-716 for the potential treatment of chronic pruritic diseases,” said Dr. John F. Paolini, MD, PhD, FACC, Chief Medical Officer at Kiniksa. Presentations include: KPL-716, Anti-OSMRß Antibody, Reduced Pruritus in Atopic Dermatitis Oral Presentation: Concurrent Mini-Symposium
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $25.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionGlobeNewswire
KNSA
Earnings
- 4/23/24 - Miss
KNSA
Sec Filings
- 4/25/24 - Form 10-Q
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEFA14A
- KNSA's page on the SEC website